We are analyzing https://link.springer.com/article/10.1186/1756-8722-6-69.

Title:
Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma | Journal of Hematology & Oncology
Description:
Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-based polychemotherapy followed by consolidation with high-dose therapy and autologous stem cell transplant in responding patients has demonstrated good feasibility with low toxicity in prospective studies and is widely used in eligible patients. In relapsed and refractory patients, who are not candidates for transplant approaches, therapeutic options are limited and are usually palliative. Several new agents are currently under investigation to improve the outcome of PTCL in the first line and salvage settings. Belinostat, a histone deacetylase (HDAC) inhibitor, has demonstrated broad antineoplastic activity in preclinical studies, and promising results in advanced relapsed/refractory lymphomas. Here, we report the case of a 73 year old patient with heavily pre-treated refractory PTCL in complete remission with belinostat for 39 months.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Law & Government

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

lymphoma, belinostat, peripheral, tcell, patient, ptcl, patients, day, article, refractory, cycles, google, scholar, lymphomas, mgm, cell, pubmed, remission, treatment, complete, chemotherapy, access, therapy, relapsed, hdac, months, prognostic, response, study, classification, oncol, authors, information, journal, case, report, open, stem, inhibitor, nonhodgkins, anaplastic, figure, treated, privacy, cookies, reimer, chawla, studies, standard, autologous,

Topics {✒️}

peripheral t-cell lymphoma peripheral t-cell lymphomas international peripheral t-cell t-cell lymphoma open-label belief-trial long-term complete remission revised european-american lymphoma open-label belinostat trial open access license related subjects /nk-cell lymphomas advanced relapsed/refractory lymphomas cyclophosphamide 750 mg/m2 day 1 article download pdf doxorubicin 50 mg/m2 day 1 b-cell lymphomas anaplastic lymphoma kinase pan-histone deacetylase inhibitor stem cell collection privacy choices/manage cookies cancer cell proliferation long lasting remission lymphoma classification project 4 mg/m2 day 1 peter reimer authors’ original file belief trial [abtract] cervical lymph nodes western countries[1–3] supraclavicular lymph nodes article reimer phase ii study clinico-pathologic study full access european economic area international prognostic index chemotherapy-refractory patients phase ii trial hdac inhibitor belinostat chemo-refractory disease refractory peripheral demonstrated good feasibility anthracycline-based polychemotherapy anthracycline-based regimens shown chemo-sensitivity alter acetylation levels staging procedures revealed relevant concomitant diseases avoid potential toxicities clostridium difficile toxin

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma
         description:Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-based polychemotherapy followed by consolidation with high-dose therapy and autologous stem cell transplant in responding patients has demonstrated good feasibility with low toxicity in prospective studies and is widely used in eligible patients. In relapsed and refractory patients, who are not candidates for transplant approaches, therapeutic options are limited and are usually palliative. Several new agents are currently under investigation to improve the outcome of PTCL in the first line and salvage settings. Belinostat, a histone deacetylase (HDAC) inhibitor, has demonstrated broad antineoplastic activity in preclinical studies, and promising results in advanced relapsed/refractory lymphomas. Here, we report the case of a 73 year old patient with heavily pre-treated refractory PTCL in complete remission with belinostat for 39 months.
         datePublished:2013-09-10T00:00:00Z
         dateModified:2013-09-10T00:00:00Z
         pageStart:1
         pageEnd:3
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/1756-8722-6-69
         keywords:
            Peripheral T-cell lymphoma
            Belinostat
            HDAC inhibitor
            Oncology
            Hematology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1756-8722-6-69/MediaObjects/13045_2013_Article_333_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1756-8722-6-69/MediaObjects/13045_2013_Article_333_Fig2_HTML.jpg
         isPartOf:
            name:Journal of Hematology & Oncology
            issn:
               1756-8722
            volumeNumber:6
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Peter Reimer
               affiliation:
                     name:Evangelisches Krankenhaus Essen-Werden gGmbH
                     address:
                        name:Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Shanta Chawla
               affiliation:
                     name:Spectrum Pharmaceuticals
                     address:
                        name:Spectrum Pharmaceuticals, Irvine, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma
      description:Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-based polychemotherapy followed by consolidation with high-dose therapy and autologous stem cell transplant in responding patients has demonstrated good feasibility with low toxicity in prospective studies and is widely used in eligible patients. In relapsed and refractory patients, who are not candidates for transplant approaches, therapeutic options are limited and are usually palliative. Several new agents are currently under investigation to improve the outcome of PTCL in the first line and salvage settings. Belinostat, a histone deacetylase (HDAC) inhibitor, has demonstrated broad antineoplastic activity in preclinical studies, and promising results in advanced relapsed/refractory lymphomas. Here, we report the case of a 73 year old patient with heavily pre-treated refractory PTCL in complete remission with belinostat for 39 months.
      datePublished:2013-09-10T00:00:00Z
      dateModified:2013-09-10T00:00:00Z
      pageStart:1
      pageEnd:3
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/1756-8722-6-69
      keywords:
         Peripheral T-cell lymphoma
         Belinostat
         HDAC inhibitor
         Oncology
         Hematology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1756-8722-6-69/MediaObjects/13045_2013_Article_333_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1756-8722-6-69/MediaObjects/13045_2013_Article_333_Fig2_HTML.jpg
      isPartOf:
         name:Journal of Hematology & Oncology
         issn:
            1756-8722
         volumeNumber:6
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Peter Reimer
            affiliation:
                  name:Evangelisches Krankenhaus Essen-Werden gGmbH
                  address:
                     name:Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Shanta Chawla
            affiliation:
                  name:Spectrum Pharmaceuticals
                  address:
                     name:Spectrum Pharmaceuticals, Irvine, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Hematology & Oncology
      issn:
         1756-8722
      volumeNumber:6
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Evangelisches Krankenhaus Essen-Werden gGmbH
      address:
         name:Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany
         type:PostalAddress
      name:Spectrum Pharmaceuticals
      address:
         name:Spectrum Pharmaceuticals, Irvine, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Peter Reimer
      affiliation:
            name:Evangelisches Krankenhaus Essen-Werden gGmbH
            address:
               name:Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Shanta Chawla
      affiliation:
            name:Spectrum Pharmaceuticals
            address:
               name:Spectrum Pharmaceuticals, Irvine, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany
      name:Spectrum Pharmaceuticals, Irvine, USA

External Links {🔗}(55)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.3s.

LINK . SPRINGER . COM {}